[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lymphomas\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lymphomas":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,74,100,123,147],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":4,"leadSponsor":42,"locationsCount":45},"100058758","specimen-collections-from-participants-with-hiv-infection-kshv-infection-viral-related-pre-malignant-lesions-and-cancer-100058758",false,"NCT00006518","Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer","Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-Malignant Lesions, and\u002For Cancer","* INCLUSION CRITERIA:\n* Age 18 years or older.\n* ECOG performance status less than or equal to 3\n\nAt least one of the following:\n\n* Exposure risk to HIV, KSHV, or HPV\n* HIV seropositive\n* KSHV seropositive\n* EBV seropositive\n* HTLV-1 seropositive\n\nNOTE: infection with HIV, KSHV, EBV, and HTLV-1 are life-long, so if participants have previously been seropositive or have had a disease associated with KSHV (KS, primary effusion lymphoma \\[PEL\\], or KSHV-multicentric Castleman s disease \\[MCD\\]), this is sufficient to meet this criterion for eligibility.\n\n* Malignancy, MCD, or skin lesions with appearance of KS\n* Cervical or anal intraepithelial lesion\n* Ability of participant to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\nNone","ALL","18 Years",{"count":19,"type":20},1029,"ESTIMATED","OBSERVATIONAL","BACKGROUND:\n\n* A number of important scientific advances can be made through the study of blood, bone marrow, tumor, or other tissue samples from patients with HIV infection, infection with Kaposi s sarcoma associated herpesvirus (KSHV), infection with other oncogenic viruses, or cancer.\n* This protocol provides a mechanism to affect a variety of such studies.\n\nOBJECTIVES:\n\n-Acquisition of serum, circulating cells, bone marrow, and tumor or normal tissue samples from participants with HIV infection, KSHV infection, or with cancer.\n\nELIGIBILITY:\n\n-Eligibility criteria include age 18 years or older and at least one of the following: Exposure risk to HIV, KSHV, or HPV; HIV seropositive; KSHV seropositive; EBV seropositive; HTLV-1 seropositive; malignancy, Castleman s disease, or skin lesions with appearance of Kaposi s sarcoma; or cervical or anal intraepithelial lesion.\n\nDESIGN:\n\n* Up to 999 subjects will be enrolled in this study.\n* Blood samples may be collected at the initial visit, and at follow-up visits.\n* Other fluids\u002Fexcretions may be collected (such as urine, saliva, semen, and stool).\n* Tumor samples may be obtained by fine needle aspirate, by removal of pleural or peritoneal fluid, by skin punch biopsy, or by excisional biopsy, providing the tumor is accessible with minimal risk to the participants.\n* Specific risks will be described in a separate consent to be obtained at the time of the biopsy.\n* Samples will be studied in the HIV and AIDS Malignancy Branch, CCR, NCI; laboratories in NCI-Frederick; or those of collaborating investigators.",[24,25,26,27,28],"HIV","Kaposi's Sarcoma","Lymphomas","Multicentric Castleman's Disease","Primary Effusion Lymphoma",[30,31,24,32,33,34],"Tumor","Viruses","KSHV","AIDS","Natural History","RECRUITING","2026-06-27",{"date":38,"type":39},"2026-06-30","ACTUAL",{"date":41,"type":39},"2000-12-06",{"name":43,"class":44},"National Cancer Institute (NCI)","NIH",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":4,"leadSponsor":72,"locationsCount":73},"100125401","collection-of-tissue-samples-for-cancer-research-100125401","NCT00900198","Collection of Tissue Samples for Cancer Research","Tissue Procurement Protocol for the Developmental Therapeutics Clinic, National Cancer Institute (NCI)","* INCLUSION CRITERIA - ADULT:\n* Patients 18 years of age and older who are being evaluated and\u002For treated for cancer at the NIH Clinical Center or at participating sites:\n\n  * Who have a newly diagnosed malignancy for which they have not yet received treatment, or\n  * Who have a previously treated malignancy that is now recurrent or currently progressing on treatment indicated by:\n\n    * radiographic evidence of tumor growth and\u002For new metastases, or\n    * CBC w\u002Fdifferential and\u002For flow cytometry, or\n    * documented evidence by the treating physician of signs\u002Fsymptoms of clinical disease progression, or\n  * Who are currently undergoing treatment and for whom disease response has not yet been assessed,\n\n    ---In this circumstance, specimen collection should occur as distant in time from the most recent drug administration as possible such as after completion of a treatment cycle and immediately prior to initiation of the next cycle.\n  * Patients with ongoing partial response (PR) or stable disease (SD) are eligible.\n\n    * For solid tumor diagnoses, confirmation of viable malignancy and\u002For \\\u003C90% tumor necrosis, fibrosis, or hemorrhage per the final pathology must be reported to the coordinating site for patients enrolled with ongoing PR or SD at the time of specimen collection.\n    * For hematologic malignancies, confirmation of viable malignancy must be reported to the coordinating site per the final flow cytometry report.\n* Ability to understand and willingness to sign a written informed consent document indicating their willingness to have their tissue or biologic fluid specimens used for research as outlined in this protocol.\n\nAt the NIH Clinical Center ONLY:\n\n* At the PIs discretion, specimens may be collected from patients 18 years of age and older prior to the development of an invasive cancer, who are being evaluated and\u002For treated for a confirmed familial cancer syndrome such as but not limited to Hereditary Breast and Ovarian Cancer (HBOC), Hereditary Non-polyposis Colorectal Cancer Syndrome or Hereditary Diffuse Gastric Cancer (HDGC) syndrome.\n* Specimens, including blood only, can be collected from patients 18 years of age and older who are being evaluated and\u002For treated for a hematologic malignancy, including Myelodysplastic Syndrome (MDS) and\u002For MDS Myeloproliferative Neoplasm (MDS-MPN), that meet all other adult eligibility criteria.\n\n  * Due to the different characteristics of hematologic malignancies versus solid tumor malignancies, including methodology for assessment of disease response, residual disease, and progression, evaluation of these factors for determination of protocol eligibility should be made utilizing established standards such as hematopathology, flow cytometry, immunohistochemical analysis, etc.\n\nEXCLUSION CRITERIA:\n\nNote: Testing for bloodborne pathogens or other infections is not required for eligibility assessment and will be performed only if clinically indicated. Exclusion criteria for bloodborne pathogens and\u002For other infections is based on existing documentation in the medical record or patient report of such diagnosis at the time of eligibility assessment, if testing is not obtained for clinical indications.\n\n* Patients with cancer-like syndromes and\u002For blood disorders such as but not limited to systemic mastocytosis, Langerhans cell histiocytosis, chronic eosinophilic leukemia\u002Fhypereosinophilic syndrome, lymphomatoid granulomatosis, or monoclonal gammopathy of undetermined significance (MGUS).\n* Patients with invasive fungal infections.\n* Patients with active and\u002For uncontrolled infections or who are still recovering from an infection:\n\n  * All antibiotics, antifungals, or antivirals prescribed for the treatment of an infection should be completed at least 1 week (7 days) prior to collection.\n  * No recurrence of fever or other symptoms related to infection for at least 1 week (7 days) following completion of antibiotics.\n  * Patients receiving antibiotics, antifungals, or antivirals for prophylaxis are permissible.\n  * Antibiotics being administered topically at a location distant from the planned tissue collection site or eye drops for a localized infection are permissible.\n  * Note: Use of antibiotics for prophylaxis is not an exclusion.\n* Patients with Human Immunodeficiency Virus (HIV), active or chronic hepatitis (i.e., quantifiable HBV-DNA and\u002For positive HbsAg, quantifiable HCV-RNA) or known history of HCV or HBV.\n* Patients with Hepatitis A as indicated by anti-HAV IgM reactivity\n\n  --Note: Patients that are anti-HAV IgG reactive only are not excluded\n* Blood only collections from patients with solid tumors or hematologic malignancy demonstrating partial or stable disease response:\n\n  * Blood will not be collected from patients whose disease demonstrates ongoing partial response or ongoing stable disease given the poor rate of model generation from such specimens.\n  * Blood will not be collected from patients between doses within a single treatment cycle.\n* Specimen collections from patients with benign tumors including but not limited to desmoid tumors, carcinoma in situ, or ongoing evidence of complete disease response (CR).\n\nINCLUSION CRITERIA - PEDIATRIC:\n\n* Patients younger than 18 years of age and older than 2 months with a histologically or cytologically confirmed diagnosis of cancer (solid tumor or hematologic malignancy) who are being treated for cancer at the NIH Clinical Center or participating clinical sites and who will already be undergoing a clinically necessary medical procedure during which tumor tissue will be resected or needle biopsy tissue or bone marrow aspirate collected. Tissue from neonates will not be collected.\n* Ability and willingness to assent to participation, utilizing an explanation that is understandable\u002Fage appropriate, as well as receiving parental permission.\n\nAt the NIH Clinical Center ONLY\n\n-At the PI s discretion, clinically indicated tissue collections may occur from patients with pediatric tumors that are generally benign but are known to undergo malignant transformation, e.g., neurofibromatosis, osteochondromas, pheochromocytoma, etc.\n\nEXCLUSION CRITERIA - PEDIATRIC:\n\nNote: Testing for bloodborne pathogens or other infections is not required for eligibility assessment and will be performed only if clinically indicated. Exclusion criteria for bloodborne pathogens and\u002For other infections is based on existing documentation in the medical record or patient report of diagnosis at the time of eligibility assessment, if testing is not obtained for clinical indications.\n\n* Patients with invasive fungal infections\n* Patients with active and\u002For uncontrolled infections or who are still recovering from an infection:\n\n  * Actively febrile patients with uncertain etiology of febrile episode\n  * All antibiotics should be completed at least 1 week (7 days) prior to collection\n  * No recurrence of fever or other symptoms related to infection for at least 1 week (7 days) following completion of antibiotics\n  * Note: Use of antibiotics for prophylaxis is not an exclusion.\n* Patients with Human Immunodeficiency Virus (HIV), active or chronic hepatitis (i.e., quantifiable HBV-DNA and\u002For positive HbsAg, quantifiable HCV-RNA) or known history of HCV or HBV.\n* Patients with Hepatitis A as indicated by anti-HAV IgM reactivity\n\n  --Note: Patients that are anti-HAV IgG reactive only are not excluded\n* Specimen collections from patients with benign tumors including but not limited to desmoid tumors, carcinoma in situ, or ongoing evidence of complete disease response (CR) based on imaging.\n* Blood only collections from patients with partial or stable disease response:\n\n  * Blood will not be collected from patients whose disease demonstrates ongoing partial response or ongoing stable disease given the poor rate of model generation from such specimens.\n  * Blood will not be collected from patients between doses within a single treatment cycle.","2 Months",{"count":55,"type":20},5000,"Background:\n\n-Patients who are being evaluated and\u002For treated at the NIH Clinical Center and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens.\n\nObjectives:\n\n* To obtain samples from adult and pediatric patients for research purposes from tests and procedures that are done as required by the primary research protocol(s) to which a patient is enrolled or as part of their standard-of-care treatment.\n* To obtain samples for research purposes from non-surgical procedures, such as percutaneous biopsies, performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol.\n\nEligibility:\n\n-Adult patients (18 years of age and older) and pediatric patients (younger than 18 years of age) who are being evaluated for and\u002For treated for cancer at the NIH Clinical Center participating sites.\n\nDesign:\n\n* This is a multicenter tissue procurement protocol with NCI as the coordinating center.\n* For adult patients: specimens for research purposes, as outlined in this protocol, will be obtained from tests and procedures that are done as required by the primary research protocols to which a patient is enrolled or as part of their standard-of-care treatment. Non-surgical procedures, such as percutaneous biopsies, may also be performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol. Tissues and biological fluids to be procured may include but are not limited to blood, serum, urine, tumor tissue, normal tissue, pleural fluid, CSF, saliva, bronchial alveolar lavage (BAL), circulating tumor cells, hair follicles, and bone marrow. These specimens will be stored with unique identifiers and used to perform only those research studies that are outlined in this protocol.\n* For pediatric patients: tumor biopsy\u002Fresection tissue used for pediatric preclinical model development will only be from tissue already being obtained as part of a procedure necessary for the patient s clinical care or as part of a primary research protocol; blood specimens will be collected as part of a blood collection already scheduled for the patient s clinical care or as part of the planned pre-procedure bloodwork; volumes collected will not exceed institutional research limits.\n* Given the risks associated with any invasive procedure, such as tumor biopsy, the procedure will be discussed in detail with the patients and their parents\u002Fguardian (as indicated), including the side effects, prior to obtaining a separate consent for each procedure. A separate consent will not be signed prior to obtaining samples by minimally invasive measures, such as venipuncture.\n* This study has two separate consent forms at the NIH Clinical Center: one for adult patients to donate specimens for ongoing research on assay development and studies of molecular pathways, and one for adult and age-appropriate pediatric patients to donate samples for the generation of preclinical models. The study also has consent form templates for adult and pediatric patients at participating sites to donate specimens to create preclinical models.\n* Patients may remain on study for the duration of their consent or completion of the planned procedure, whichever comes first.",[58,26,59,60],"Neoplasms","Multiple Myeloma","Myelodysplastic Syndrome",[62,63,64,65,66,34],"Tissue Collection","Biospecimen","Assay Development","Tissue Acquisition","Tissue Biopsies","2026-05-29",{"date":69,"type":39},"2026-06-01",{"date":71,"type":39},"2006-07-06",{"name":43,"class":44},17,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":45},"100498652","phase-1-a-phase-1-study-of-jv-213-autologous-cd79b-targeting-chimeric-antigen-receptor-t-cell-therapy-in-adults-with-relapsed-or-refractory-b-cell-lymphomas-100498652","NCT05773040","A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas","Inclusion Criteria:\n\nPatients must meet the following inclusion criteria in order to be eligible for participation in this trial:\n\n1. For the dose escalation cohort: Eligible patients will include those with r\u002Fr B-cell lymphoma including LBCL (DLBCL, HGBCL, LBCL transformed from indolent lymphoma, and PMBCL), FL, marginal zone lymphoma, and MCL after at least 2 prior systemic therapies and Burkitt lymphoma after at least 1 prior systemic therapy. For the dose expansion cohort: Patients with r\u002Fr LBCL (DLBCL, HGBCL, LBCL transformed from indolent lymphoma, and PMBCL) and FL grade 3B will be eligible\n2. Received at least 2 prior lines of therapy, including anti-CD20 antibody and anthracycline therapy for LBCL, anti-CD20 antibody and alkylating agent or lenalidomide therapy for FL, anti-CD20 antibody and alkylating agent or lenalidomide or BTK inhibitor therapy for marginal zone lymphoma, and anti-CD20 antibody and alkylating agent or BTK inhibitor therapy for MCL. Patients with Burkitt lymphoma may be eligible after 1 line of prior therapy including anti-CD20 antibody and anthracycline therapy.\n3. Patients who have received prior CD19 CAR cell therapy using FMC63 antibody for targeting CD19 are eligible and must be at least 6 weeks post CAR infusion and have \\\u003C5% of peripheral blood T cells expressing the prior CAR by flow cytometry assessment.\n4. ≥18 years of age\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n6. At least one measurable lesion per the Lugano 2014 Classification53\n7. At least two weeks or 5 half-lives, whichever is shorter, must have elapsed since any prior systemic anti-cancer therapy prior to leukapheresis. For patients treated with monoclonal antibody-based therapies, at least 4 weeks must have elapsed prior to leukapheresis.\n8. Toxicities due to prior therapy must be stable and recovered to ≤grade 1 (except for clinically non-significant toxicities such as alopecia)\n9. Absolute neutrophil count of ≥1.0×10\\^9\u002FL\n10. Absolute lymphocyte count of ≥0.1×10\\^9\u002FL\n11. Platelet count of ≥75×10\\^9\u002FL\n12. Creatinine clearance (as estimated by Cockcroft Gault) ≥45 mL\u002Fmin\n13. Serum alanine transaminase (ALT) \u002F aspartate transaminase (AST) ≤5 times the upper limit of normal (ULN)\n14. Total bilirubin ≤2 mg\u002FdL, except in patients with Gilbert's syndrome.\n15. Cardiac ejection fraction ≥45% with no evidence of clinically significant pericardial effusion\n16. Baseline oxygen saturation ≥92% on room air\n17. Women of childbearing potential must have a negative serum or urine pregnancy test (women who have had hysterectomy and women who are over the age of 45 years and\n\nExclusion Criteria:\n\nPatients will be excluded from participating in the trial if he\u002Fshe has:\n\n1. Active central nervous system (CNS) lymphoma including patients with detectable cerebrospinal fluid malignant cells or brain metastases. Patients with prior CNS lymphoma that has been effectively treated will be eligible if treatment was completed at least one year prior to enrolment and there is no evidence of disease on MRI with gadolinium contrast at the time of screening.\n2. Any CAR cell therapy using non-FMC63 antibody.\n3. History of Richter's transformation of chronic lymphocytic leukemia\n4. Autologous stem cell transplantation within 6 weeks.\n5. Allogeneic stem cell transplantation within 3 months or active graft versus host disease.\n6. Active autoimmune disease (e.g. Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus) requiring systemic immunosuppression\u002Fsystemic disease modifying agents within the last 1 year or inflammatory disease (including graft versus host disease) requiring systemic immunosuppressive therapy. Physiological replacement of corticosteroids of up to 7.5 mg of prednisone or equivalent per day, and topical and inhaled corticosteroids are permitted.\n7. History of any form of primary immunodeficiency that in the opinion of the investigator may affect efficacy of the CAR-T product.\n8. History of any one of the following cardiovascular conditions within the past 6 months: Class III or IV heart failure as defined by the New York Heart Association, cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other clinically significant cardiac disease.\n9. History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) unless disease free for at least 2 years and treated with curative intent. Patients with a prior history of malignancy whose natural history or treatment (e.g. hormonal therapy) does not have the potential to interfere with either the safety or efficacy assessment of the investigational regimen in the opinion of the investigator may be included.\n10. Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring intravenous antimicrobials for management. Simple urinary tract infection and uncomplicated bacterial pharyngitis or localized skin infections are permitted if responding to active treatment and after consultation with the Principal Investigator.\n11. Known history of infection with HIV or hepatitis B (HBsAg positive) or hepatitis C virus (anti-HCV positive). A history of hepatitis B or hepatitis C is permitted if the viral load is undetectable per quantitative PCR and\u002For nucleic acid testing.\n12. History or presence of CNS disorders such as seizure disorder, cerebrovascular ischemia\u002Fhemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement\n13. Patients with cardiac atrial or cardiac ventricular lymphoma involvement\n14. Requirement for urgent therapy due to tumor mass effect such as bowel obstruction or blood vessel compression\n15. Any medical condition likely to interfere with assessment of safety or efficacy of study treatment\n16. Live vaccine ≤6 weeks prior to planned start of conditioning regimen\n17. Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the conditioning chemotherapy on the fetus or infant.\n18. Females of childbearing potential and males of child fathering potential who are not willing to practice two methods of birth control from the time of consent through 6 months after infusion of the study drug\n19. In the investigator's judgment, the patient is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation.",{"count":81,"type":20},33,"INTERVENTIONAL",[84],"PHASE1","To find the highest tolerable dose of JV-213 (a type of autologous CAR T cell therapy) that can be given to patients who have B-cell lymphoma that is relapsed or refractory.",[26,87],"B-cell Lymphomas",[89],"B-cell lymphoma, CD79b, CAR T cell therapy","2026-05-14",{"date":92,"type":39},"2026-05-18",{"date":94,"type":39},"2023-04-14",{"date":96,"type":20},"2028-12-31",{"name":98,"class":99},"M.D. Anderson Cancer Center","OTHER",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":82,"phases":110,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":45},"100394572","interest-of-individual-biomarkers-from-the-identification-of-tumor-genotype-by-high-throughput-molecular-techniques-100394572","NCT04417803","Interest of Individual Biomarkers From the Identification of Tumor Genotype by High-throughput Molecular Techniques","Interest of Individual Biomarkers From the Identification of Tumor Genotype in Plasma (ctDNA: Circulating Tumor DNA) by High-throughput Molecular Next Generation Techniques(CAPP Seq, PhAsE Seq, VIRCAPP-seq) in the Diagnosis and Personalized Management of Lymphomas in a Prospective Monocentric Cohort","BIOLYMPH2020","Inclusion Criteria:\n\n* Person who has not opposed to their inclusion in the trial\n* Confirmation of the diagnosis of one of the lymphomas (DGLBL, LF, classic LH, LT or LCM) according to the WHO 2016 international classification (Smerdlow et al, 2016)\n* Patients not currently taking treatment for their haemopathy (or who have received corticosteroid therapy alone within 14 days prior to the 1st sampling, dose limited to 500mg total)\n* Patients requiring systemic treatment within 30 days of screening\n\nExclusion Criteria:\n\n* Person subject to legal protection (curatorship, guardianship)\n* Person under partial judicial control\n* Pregnant, parturient or breastfeeding woman\n* Adult incapable or incapable to express his or her non-opposition\n* Minor\n* Localized lymphoma treated by surgery and\u002For localized radiotherapy",{"count":109,"type":20},1200,[111],"NA","Lymphomas are the most common haemopathic malignancy. The 3 most common types are diffuse large B-cell lymphoma (DLBCL), Hodgkin's lymphoma (HL) and follicular lymphoma (FL). In these three subtypes, the treatment strategy is most often curative. The therapeutic strategy is guided by PET (positron emission tomography), which optimises the risk-benefit balance between the efficacy and toxicity of the treatment and makes it possible to limit the intensity of treatment for good responders and to intensify the treatment of poor responders with a worse prognosis. PET therefore plays a central role in the pre-therapeutic evaluation of the disease and in the assessment of response to treatment. However, other complementary approaches could improve characterization prior to initiating lymphoma t-treatment and individual patient management during treatment and beyond. In DLBCL, it has been shown that the risk of relapse of good and bad responders is decreased by combining the PET response with a reduction in the amount of tumor DNA (ctDNA) in the blood, i.e. the genetic program of lymphoma cells that circulates freely in the blood. This evaluation of ctDNA has been made possible by the development of innovative techniques such as Next Generation Sequencing (NGS). In lymphomas, several approaches have been developed, the most sensitive and promising being CAPP-Seq (CAncer Personalized Profiling by deep Sequencing) developed at Stanford University.\n\nIt is therefore useful to study the description of ctDNA in the 3 types of lymphomas and to analyse the progression profiles under treatment by trying to establish the major potential usefulness of these techniques: modifying treatment in case of poor response based on ctDNA +\u002F- and PET, detecting relapses earlier than at present in patients without any other sign of relapse (clinical, blood or PET).\n\nThe project presented here aims to build a collection of plasma samples taken before treatment, during treatment and during the first 2 years of follow-up in patients with one of the 3 most frequent types of lymphoma and undergoing curative treatment. The hypothesis is that sequential evaluation of ctDNA could improve the individualized management of future patients based on the results generated by the analyses of patients in this cohort.\n\nGiven the progress made in setting up this tool for DLBCL and HL, it is highly appropriate to explore its potential usefulness in other subtypes such as mantle cell lymphoma (MCL) and T-cell lymphoma (TL).",[26],"2025-06-06",{"date":116,"type":39},"2025-06-11",{"date":118,"type":39},"2021-05-17",{"date":120,"type":20},"2046-05",{"name":122,"class":99},"Centre Hospitalier Universitaire Dijon",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":82,"phases":131,"briefSummary":133,"conditions":134,"keywords":135,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":145,"locationsCount":45},"100593104","phase-2-selinexor-high-dose-methotrexate-and-rituximab-combined-with-radiotherapy-for-newly-diagnosed-transplant-ineligible-patients-with-central-nervous-system-lymphoma-an-open-label-single-arm-multicenter-phase-ii-study-100593104","NCT07002099","Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study","Inclusion Criteria:\n\n1. Age ≥ 18 years, male or female.\n2. Histologically confirmed primary CNS lymphoma (PCNSL) or secondary CNS lymphoma (SCNSL) with CNS-only involvement.\n3. Ineligible for autologous stem cell transplantation based on clinical assessment or patient refusal.\n4. At least one measurable brain lesion ≥1 cm in diameter, or positive cerebrospinal fluid (CSF) cytology\u002Fflow cytometry for patients with leptomeningeal disease.\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-3.\n6. Adequate organ function, including:\n\n   * Absolute neutrophil count (ANC) ≥ 1.0 × 10⁹\u002FL\n   * Platelets ≥ 75 × 10⁹\u002FL\n   * Hemoglobin ≥ 80 g\u002FL\n   * Total bilirubin ≤ 1.5 × ULN (or ≤ 3 × ULN if liver involvement)\n   * ALT and AST ≤ 2.5 × ULN (or ≤ 5 × ULN if liver involvement)\n   * Creatinine clearance ≥ 30 mL\u002Fmin (Cockcroft-Gault formula)\n   * INR ≤ 1.5 × ULN; APTT within 10 seconds of normal\n7. Estimated life expectancy of ≥ 3 months.\n8. Negative serum pregnancy test for women of childbearing potential.\n9. Ability to understand and willingness to sign a written informed consent form.\n\nExclusion Criteria:\n\n1. CNS involvement limited to intraocular lymphoma only.\n2. Prior systemic therapy for CNS lymphoma.\n3. SCNSL with active systemic (non-CNS) disease involvement.\n4. Uncontrolled intracranial hypertension.\n5. Clinically significant or unstable cardiovascular disease, including:\n\n   * Myocardial infarction within 6 months\n   * Unstable angina within 3 months\n   * Uncontrolled arrhythmias (e.g., ventricular tachycardia\u002Ffibrillation)\n   * Congestive heart failure NYHA class ≥ III\n   * LVEF \\\u003C 50% by echocardiography\n6. Other severe uncontrolled medical conditions, including active infections requiring systemic therapy.\n7. Known active hepatitis B (HBV), hepatitis C (HCV), or HIV infection.\n8. Active gastrointestinal dysfunction that interferes with the ability to swallow or absorb oral medication.\n9. Prior treatment with selective inhibitor of nuclear export (SINE) compounds, including selinexor.\n10. Concurrent malignancy, except for adequately treated basal\u002Fsquamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ of the cervix, prostate, or breast.\n11. Pregnant or breastfeeding women, or subjects unwilling to use medically accepted effective contraception during the study and for 6 months after the last dose.\n12. Any condition which, in the investigator's judgment, would make the patient unsuitable for study participation.",{"count":130,"type":20},26,[132],"PHASE2","This phase II clinical trial is designed to evaluate a novel combination treatment for patients with newly diagnosed central nervous system lymphoma (CNSL) who are not candidates for stem cell transplantation. The study will assess the safety and effectiveness of combining selinexor (an oral selective nuclear export inhibitor) with high-dose methotrexate and rituximab chemotherapy, followed by low-dose whole-brain radiotherapy (WBRT). Selinexor has shown promise in enhancing the effects of chemotherapy and radiation in blood cancers.\n\nPatients enrolled in this open-label, single-arm, multicenter study will receive up to six 21-day treatment cycles. Those who respond well will undergo reduced-dose WBRT and continue selinexor as maintenance therapy. The study will measure how many patients respond to the treatment (overall response rate), how long the response lasts (progression-free survival), overall survival, and safety.\n\nThis research aims to provide a less toxic and more effective option for treating CNSL in patients who are older or medically unfit for transplantation.",[26],[136,137,138],"Selinexor","central nervous system lymphoma","WBRT","2025-05-23",{"date":141,"type":39},"2025-06-03",{"date":143,"type":20},"2025-06-01",{"date":96,"type":20},{"name":146,"class":99},"Second Affiliated Hospital of Soochow University",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":16,"minAge":155,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":82,"phases":159,"briefSummary":160,"conditions":161,"keywords":163,"overallStatus":166,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":45},"100565834","phase-1-car-t-technology-for-recurrentrefractory-malignant-hematological-and-lymphatic-tumors-100565834","NCT06647329","CAR-T Technology for Recurrent\u002FRefractory Malignant Hematological and Lymphatic Tumors","CAR-T Technology for the Treatment of Recurrent\u002FRefractory Malignant Hematological and Lymphatic Tumors: Multi-Center Clinical Study on Safety and Efficacy","CAR-T Therapy","Inclusion Criteria:\n\n\\-\n\nParticipants must meet all of the following conditions to be included:\n\n1. The participant has given informed consent and signed the consent form, and is willing and capable of complying with the scheduled visits, study treatment, laboratory examinations, and other trial procedures.\n2. Clinically diagnosed as having relapsed\u002Frefractory malignant hematologic tumors:\n\n   2.1 Diagnosed as CD19+ and\u002For CD20+ and\u002For CD22+ B-cell tumors through pathological and histological examinations, and the participant meets the criteria for relapsed or refractory B-cell malignancies as follows:\n\n   B-cell tumors include the following three categories:\n\n   A. B-cell acute lymphoblastic leukemia (B-ALL); B. Indolent B-cell lymphomas (CLL, FL, MZL, LPL, HCL); C. Aggressive B-cell lymphomas (DLBCL, BL, MCL).\n\n   2.1.1. Refractory\u002Frelapsed B-cell leukemia (meeting one of the following four criteria): A. Relapse within 6 months after initial remission; B. Initial refractory after 2 cycles of standard chemotherapy without achieving complete remission; C. Relapse or refractory after first-line or multi-line salvage chemotherapy without achieving complete remission; D. Not suitable for hematopoietic stem cell transplantation, or have abandoned transplantation due to conditions, or relapse after transplantation.\n\n   2.1.2. Refractory\u002Frelapsed B-cell lymphoma (meeting one of the first four criteria plus the fifth): A. Tumor shrinkage of less than 50% or disease progression after 4 cycles of standard chemotherapy; B. Achieved CR after standard chemotherapy, but relapsed within 6 months; C. Relapsed 2 times or more after achieving CR; D. Not suitable for hematopoietic stem cell transplantation, or have abandoned transplantation due to conditions, or relapse after transplantation;\n\n   E. The participant must have received sufficient prior treatment, including at least:\n   1. Anti-CD20 monoclonal antibodies\n   2. Combination chemotherapy containing anthracyclines.\n\n   2.2 Refractory\u002Frelapsed multiple myeloma: Progressed after at least 3 lines of treatment (at least one proteasome inhibitor and one immunomodulator used).\n\n   2.3 Presence of measurable or evaluable lesions: A. For lymphoma patients, a single lesion ≥15 mm or two or more lesions ≥10 mm, or PET-positive lesions determined according to Lugano criteria; B. For leukemia and myeloma patients, bone marrow MRD must be persistently positive or positive relapse.\n3. Age 14-75 years (inclusive), both male and female.\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n5. Treatment-related antigen test results must be positive:\n\n   A. For lymphoma: CD19\u002FCD20\u002FCD22 (immunohistochemical results positive within six months); B. For acute lymphoblastic leukemia: CD19\u002FCD22 (tumor cells detected positive by flow cytometry in bone marrow at screening, or extramedullary lesions with positive immunohistochemistry results within six months); C.For multiple myeloma: BCMA (tumor cells detected positive by flow cytometry in bone marrow at screening, or extramedullary lesions with positive immunohistochemistry results within six months).\n6. Expected survival time greater than 3 months from the date of signing the informed consent form.\n7. HGB ≥ 70 g\u002FL (transfusion allowed).\n8. Liver and kidney function, and cardiopulmonary function must meet the following requirements: a) Creatinine ≤ 1.5 × ULN; b) Left ventricular ejection fraction ≥ 50%; c) Blood oxygen saturation \\> 90%; d) Total bilirubin ≤ 1.5 × ULN; ALT and AST ≤ 2.5 × ULN.\n9. Participants with a plan for pregnancy must agree to use contraception before enrollment and for six months after the study begins; if the participant becomes pregnant or suspects pregnancy, they must immediately notify the investigator.\n\nExclusion Criteria:\n\nParticipants who meet any of the following conditions are not eligible for inclusion:\n\n1. History of any of the following cardiovascular diseases within the past 6 months: New York Heart Association (NYHA) class III or IV heart failure, cardiovascular intervention (angioplasty or stenting), myocardial infarction, unstable angina, or other clinically significant heart diseases.\n2. History of severe pulmonary dysfunction.\n3. Concurrent advanced malignant tumors.\n4. Concurrent systemic fungal, bacterial, viral, or other infections that cannot be effectively controlled.\n5. Concurrent severe autoimmune diseases or congenital immunodeficiency.\n6. Active hepatitis (positive HBV DNA or HCV RNA testing).\n7. Human Immunodeficiency Virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), or syphilis infection.\n8. History of severe allergic reactions to biologics (including antibiotics).\n9. Less than 6 months since undergoing allogeneic hematopoietic stem cell transplantation.\n10. Acute or chronic graft-versus-host disease (GvHD).\n11. History of deep vein thrombosis (DVT) (cancer-related thrombosis) or pulmonary embolism (PE) within 3 months prior to signing the informed consent form.\n12. Anticoagulation treatment for DVT or PE within 3 months prior to signing the informed consent form.\n13. History or clinical significance of CNS diseases at screening, such as epilepsy, seizure disorders, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or mental disorders.\n14. Pregnant or breastfeeding women. Women of childbearing potential must have a negative serum pregnancy test within 48 hours prior to the start of lymphocyte-depleting chemotherapy.\n15. Use of any of the following medications or treatments within the specified time before leukapheresis:\n\n    A. Use of alemtuzumab within the past 6 months prior to leukapheresis; B. Use of anti-CD20 monoclonal antibodies within 7 days prior to leukapheresis; C. Use of Venetoclax within 4 days prior to leukapheresis; D. Use of lenalidomide within 3 days prior to leukapheresis; E. Use of Idelalisib within 2 days prior to leukapheresis; F. Use of therapeutic doses of corticosteroids (defined as prednisone or equivalent \\> 20 mg\u002Fday) within 7 days prior to leukapheresis or 72 hours prior to CAR-T administration. However, physiological replacement, topical, and inhaled steroids are permitted; G. Use of investigational drugs within 4 weeks prior to leukapheresis. However, if treatment was ineffective or the disease progressed during the trial and at least 3 half-lives have elapsed before leukapheresis, enrollment is allowed; H. Received donor lymphocyte infusion (DLI) within 6 weeks prior to CAR-T administration.\n16. Any factors judged by the investigator that may affect compliance with the study protocol, including uncontrollable medical, psychological, familial, sociological, or geographical factors, or unwillingness or inability to comply with the required procedures of the study protocol.","14 Years","75 Years",{"count":158,"type":20},30,[84],"evaluate the safety and Esfficacy of CAR-T technology for the treatment of recurrent\u002Frefractory malignant hematological lymphomas",[162,26],"CAR-T Cell Therapy",[164,165],"CAR-T therapy","Recurrent\u002FRefractory Malignant Hematological Lymphomas","NOT_YET_RECRUITING","2024-10-16",{"date":169,"type":39},"2024-10-17",{"date":171,"type":20},"2024-12-01",{"date":173,"type":20},"2026-12-31",{"name":175,"class":99},"Mingzhi Zhang"]